Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Movymia

Sanofi reception

Sanofi predicts end of patent cliff in 2013

New launches to overcome generic competition

- PMLiVE

Sanofi backs SMS chemotherapy compliance programme

Prost8Care delivers timed text message encouragement to cancer patients

- PMLiVE

Sanofi launches voice-guided epinephrine auto-injector in US

Auvi-Q extends pharma company's interests in innovative devices

- PMLiVE

Sanofi receives EU approvals for diabetes and cancer drugs

Zaltrap and Lyxumia granted marketing authorisation by European Commission

- PMLiVE

Biosimilars in China

Tipping the balance: risks and opportunities in biosimilars

- PMLiVE

Merck & Co shares fall on Q4 results, osteoporosis drug delay

Sales down on loss of patent protection for Singulair

- PMLiVE

Bayer’s Diane 35 faces ban in France

Follows investigation into blood clot-related deaths

Sanofi reception

US approval for Sanofi’s Kynamro in genetic cholesterol disorder

Comes one month after drug was turned down in Europe due to safety concerns

- PMLiVE

EMA starts contraceptive safety probe

Follows French investigation into Bayer’s Diane 35

Novartis building

Novartis withdraws application for Ruvise approval in EU

Had submitted imatinib mesylate for use in hypertension

- PMLiVE

EMA publishes marketing application guidance for pharma

Aims to clarify what to include in summaries of product characteristics

- PMLiVE

EU nod for Novo Nordisk’s Tresiba and Ryzodeg

Reduced risk of hypoglycaemia may give insulin products edge ahead of Sanofi’s Lantus

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links